NCT03990961

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations

Conditions

• Diffuse Large B Cell Lymphoma
• Lymphoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).

Timeline

• Start date: 2019-09-04
• Primary completion: 2024-04-01
• Completion: 2024-04-01
• First posted: 2019-06-19
• Last updated: 2026-02-20
• Results posted: 2026-02-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study